Abstract: In alternative embodiments, provided are solutions for peritoneal dialysis for use for maintaining or restoring the removal of small solutes and fluids in subjects with end-stage renal disease and/or congestive heart failure. In alternative embodiments, such solutions comprise carnitine, xylitol and at least one of glucose, glycerol and polydextrin.

Abstract: Compositions for regeneration of inner cells and for treating hearing loss comprise at least one modulator of mechanistic target of rapamycin (mTOR) sufficient to induce reprogramming proliferation and regeneration of inner ear cells. The composition include, in some instances, an effective amount of one or more phosphatase and tensin homolog (PTEN) inhibitors, MYC/NOTCH modulators, Atonal Homolog 1 (Atoh1) modulators or combinations thereof.

Abstract: The present invention relates to a composition for inhibiting PAR2 activity including punicalagin, and more specifically, the present invention provides a composition for inhibiting PAR2 activity including punicalagin, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition, health functional food composition, or cosmetic composition for preventing or treating an inflammatory disease or pruritis.

Abstract: The invention describes ophthalmic pharmaceutical formulations comprising pharmaceutical ingredients to address DED symptoms. In one aspect of the invention, an ophthalmic pharmaceutical formulation comprises: 1) lubricity-promoting ingredient(s) such as those listed in the FDA over the counter (OTC) monograph for ophthalmics as demulcents and 2) surfactant(s) that solubilize lipids, assist in lubrication, and assist in easily spreading over hydrophobic surfaces; and/or 3) lipid and/or plant oil ingredient(s) that assist in film formation and the spreading of tear fluid while promoting (or at least not inhibiting) lubrication; and/or 4) mucoadhesive and viscosity promoting polymer(s) that demonstrate shear thinning flow behavior. The pharmaceutical ingredients and osmoprotectant/tonicity ingredients are combined with ingredients that provide direct to the eye nutritional support that is comprehensive in nature.

Abstract: Provided is a use of fibers formed of ?-1-4-glucan in manufacturing a composition for preventing or treating diarrhea, constipation or irritable bowel syndrome, wherein the fibers have a diameter between 15 nm to 35 nm and a mean length of between 1.5 ?m and 3.5 ?m. Also provided is a method for preventing or treating diarrhea, constipation or irritable bowel syndrome with the fibers formed of ?-1-4-glucan.

Abstract: The present disclosure discloses a method for extracting pectin rich in RG-I, in particular to an ultrasound and pressure assisted method for extracting pectin rich in RG-I. The main process includes: dispersing sieved citrus peel powers in alkaline solution containing sodium borohydride (20 to 50 mM); performing an ultrasound and pressure combined treatment on the above solution at 25 to 40° C., the treatment conditions include: static pressure of 0.2 to 0.4 MPa, ultrasonic intensity of 0.5 to 3.5 W/mL, and treatment time of 20 to 40 min; centrifuging the ultrasonically processed solution to remove residues, and sequentially carrying out precipitation with ethanol (50% to 80% v/v), precipitant dialysis (3000 to 3500 Da), and vacuum freeze drying on the extracted solution to obtain pectic polysaccharide.

Abstract: An ophthalmically compatible solution includes (a) about 0.005 to about 2 wt. %, based on the total weight of the ophthalmically compatible solution, of hyaluronic acid or a salt thereof; (b) about 0.01 to about 1 wt. %, based on the total weight of the ophthalmically compatible solution, of erythritol; (c) sodium chloride, potassium chloride or any combination thereof; and (d) one or more buffers.

Abstract: Provided herein are ionic liquids that can be used as antifungal agents alone or in combination with Amphotericin B. Also disclosed are methods of synthesis of the ionic liquids and inhibiting fungal growth and methods of treating fungal infections using the disclosed compounds. The disclosure provides antifungal agents that potentiate the antifungal activity of Amphotericin B, a commonly used antifungal drug that could be used alone or in combination. This combination will help control and combat the infections caused by drug resistant Candida. auris in immunocompromised patients.

Abstract: The invention relates to a nutraceutical formulation of blueberry extract, fish oil (omega-3 and omega-6), recombinant human lactoferrin, vitamin A and vitamin E, for human oral consumption. The invention belongs to the field of ophthalmology and has been developed as a coadjuvant for preserving the health of the precorneal film and of the eye surface. This formulation contains an extract of natural origin (Vaccinium myrtillus L) with antioxidant and anti-inflammatory properties; it also uses eicosapentaenoic acid (EPA), omega-6, and docosahexaenoic acid (DHA), omega-3, obtained from fish oil and which, together with lactoferrin, vitamin A and vitamin E, improves tear quality, since these compounds have anti-microbial and anti-inflammatory effects. This formulation has been designed as a coadjuvant for preserving the health of the precorneal film.

Abstract: This invention refers to pharmaceutical compositions containing synergistic combinations of pentacyclic triterpenoids as active principles and denotes that some specific combinations between these types of drugs exhibit effects for the prevention or inhibition of viral infections. The compositions are found in specific quantities and proportions that enhance the pharmacological properties of the compounds, improving their bioavailability and pharmacokinetic properties, while reducing their toxicological and irritability effects, especially in the respiratory tract and the lungs.

Abstract: The present disclosure relates to an aqueous composition stored in a single unit dosage container, where the aqueous composition consists of glucose, sodium bicarbonate, water, and a pH adjusting agent if needed to adjust the pH, wherein the pH of the composition is from 6.7 to 8.1. Such composition is stable for at least 3 months at room temperature conditions.

Abstract: The disclosure provides a method of joint repair or replacement in a mammal including surgically debriding a joint, administering a composition including a therapeutically effective amount of protocatechuic acid for between about 1 day and 1 month prior to arthroscopically debriding the joint, and administering the composition for between 1 day and 6 months after arthroscopically debriding the joint. The administration of the composition may be through oral administration. The composition may be a tablet, a pill, or a capsule. The tablet, the pill, or the capsule may include about 500 mg of protocatechuic acid.

Abstract: The present disclosure relates to methods of treating chronic conditions of the eye, such as dry eye disease and blepharitis, as well as to methods for increasing secretion of meibum. This disclosure also relates to formulations suitable for treating chronic conditions of the eye such as dry eye disease and blepharitis.

Abstract: The present invention provides a method for preparing a colour-stable preparation of a magnesium chlorophyllin alkali metal salt or alkali earth metal salt from natural sources of chlorophyll. The invention further provides a colour-stable and substantially pure pigment composition comprising a vibrant green magnesium chlorophyllin in the form of an alkali metal or alkali earth metal salt, e.g. those prepared by the methods of the invention, and the use of the salts and compositions of the invention as colouring agents, in particular as food colouring agents, and as medicaments and disinfectants.

Abstract: The present disclosure relates to methods of feeding animals by providing feed additives that modulate the gut microbiome to improve the health, nutrition, and growth performance. The present disclosure further relates to methods of modulating the microbial species present in the gastrointestinal tract of an animal. Such modulation includes, for example, modulating the level or function of microbial species.

Abstract: A method of producing an injectable gel product is provided, comprising (a) cross-linking a first glycosaminoglycan (GAG) with a first crosslinking agent to produce a gel, wherein the charging ratio of crosslinking agent to disaccharide unit is below 0.15; (b) preparing particles of the gel; (c) mixing the glycosaminoglycan (GAG) gel particles with a second GAG to provide a mixture; (d) cross-linking the mixture with a second crosslinking agent to obtain cross-linking between the GAGs of the second, outer phase, thereby providing a gel having a first, inner phase of the cross-linked GAG gel particles, embedded in a gel of the second GAG outer phase; and (e) preparing injectable particles, each such particle containing a plurality of the cross-linked GAG gel particles of the first, inner phase. An injectable gel product, an aqueous composition, and a pre-filled syringe as also provided.

Abstract: Botanical extracts are provided, which comprise ethanol extracts of Nannochloropsis algae having between 1 wt % and 50 wt % polar lipids and between 45 wt % and 60 wt % fatty acids, wherein the fatty acids comprise more than 10 wt % of eicosapentaenoic acid (EPA) as triglyceride conjugates and/or diglyceride conjugates, and less than 15 wt % EPA as free fatty acids. EPA level may reach up to 90 wt %, and the botanical extract may be fluid at room temperature. Growth conditions are configured, adjusted and monitored to promote EPA formation in the cell vacuoles, resulting in a high proportion of EPA as tri/di-glyceride conjugates, as well as in a high concentration of ?-3 fatty acids, which merely requires gentle extraction procedures to reach the final products, thereby maintaining the biochemical of the compounds without excessive modifications.

Abstract: Compounds, compositions, and methods for treatment and/or prevention of at least one disease, disorder, and/or condition by inhibiting binding of an E-selectin to an E-selectin ligand are disclosed. For example, E-selectin antagonists are described and pharmaceutical compositions comprising at least one of the same.

Abstract: Disclosed herein are novel compositions and methods for the treatment of inflammation. Also described herein are methods for the identification of agents useful in the foregoing methods. The invention relates to methods for treatment and prevention of disorders associated with inflammation by administering agents that may also increase levels of NAD+, such as NAD+ precursors or agents involved in NAD+ biosynthesis.

Abstract: The present invention relates to antimicrobial formulations comprising Vitamin D as carrier loaded with an antibiotic. More specifically, the present invention relates to antimicrobial compositions comprising vitamin D as carrier loaded with an antibiotic for controlling infections and managing potentially infected wounds or infected wounds or treating infected implants used in orthopaedic surgery and various other conditions leading to healing of the wounds and avoidance of development of antibacterial resistance and avoiding complications related to the use of prolonged antibiotics by systemic route.